Navigation Links
Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
Date:5/28/2008

Prevalent COPD Population Will Rise by Nearly 19 Percent as a Result of

Increased Diagnosis Rates, According to a New Report from Decision

Resources

WALTHAM, Mass., May 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launches of emerging therapies, especially the long-acting beta2 agonist/inhaled corticosteroid combination drug class, will drive sales in the chronic obstructive pulmonary disease (COPD) drug market to more than $11 billion in 2017.

The new Pharmacor report entitled Chronic Obstructive Pulmonary Disease finds that, among the emerging combination therapies, Novartis/Schering-Plough's indacaterol/mometasone and GlaxoSmithKline/Theravance's GW-642444/GW-685698 will experience annual growth of 60 percent and 71 percent, respectively, between 2012 and 2017 as a result of greater uptake of these once-daily, fixed-dose combination drugs. The market will also be driven by increased diagnosis rates in the next 10 years as the prevalent COPD population will rise by nearly 19 percent as a result of aging populations in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

Although the COPD drug market in 2007 totaled just $6.6 billion, the market has yet to realize its maximum commercial potential, according to the report. Tapping into this great market opportunity will require significant improvements in diagnosis as well as the availability of more effective drug treatments, particularly therapies that address COPD-specific pathology.

"Although disease-modifying therapies are needed, treatments that provide symptomatic relief for COPD will remain the mainstay of treatment through 2017," said Regina Jammen, analyst at Decision Resources. "The market will shift from monotherapy use, as well as from the use of twice-daily dosed therapies, to combination treatments and once-daily dosed therapies as these drugs emerge from clinical development. Each major drug class will see the emergence of new once-daily dosed products, except for drug classes that are exclusively short-acting."

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Computers help chemists fight emerging infections
2. Expert on Emerging Infectious Zoonotic Diseases Joining K-State as a Regents Distinguished Professor
3. iCAD to Present at Americas Growth Capital 4th Annual Emerging Growth Conference
4. GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology
5. Plastic Surgery 2007: Where Truth Behind Emerging Cosmetic Treatments Meets Amazing Reconstructive Advances
6. HealthShares(TM) Announces Change to the HealthShares(TM) Emerging Cancer Index
7. Targets on the horizon: Emerging therapies and novel targets
8. Emerging therapies with a focus on Asian populations mark the AACR Centennial Conference
9. Food and Drug Law Institute, Project on Emerging Nanotechnologies Co-Sponsor Major Conference on Nanotechnology Law, Regulation and Policy
10. OneMedPlace Emerging Healthcare Technologies Finance Forum Jan 7, 8th
11. QED International Associates Announces Changes to the HealthShares(TM) Emerging Cancer Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... CT (PRWEB) , ... March 29, 2017 , ... HealthCareMandA.com ... —on Thursday, April 20, 2017, at 1:00 PM ET. A recording of the webinar ... the Interactive Webinar Series. , Home health and hospice companies are still popular targets ...
(Date:3/29/2017)... ... 2017 , ... Immunotherapy has emerged as one of the most promising options ... be the next revolution in our fight against this complex disease. One of the ... checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single analyte ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... Pittsburgh now have easier access to the robotic-assisted total-hip and partial-knee replacement ... (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital recently started performing ...
(Date:3/29/2017)... PA (PRWEB) , ... March 29, 2017 , ... The ... W’80, WG’81, and Julie Taffet Moelis, W’81, have made a $10 million gift to ... deferred admission opportunity that will provide a pathway to a Wharton MBA for highly-qualified ...
(Date:3/29/2017)... ... ... has helped over 1.5 million SharePoint users learn the content management system faster and ... for SharePoint was at the farm level. Enterprises using SharePoint Online in Office 365 ... recently released a modified version of the Help System, VisualSP for Site Collections, which ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... -- According to a new market research report "Medical Radiation ... Survey Meter, Solid-State), Products (Personal Dosimeters, OSL, Badges), Safety (Apron, Shields, Face ... market is expected to reach USD 1,215.4 Million by 2021 from USD ... 2021. Continue Reading ... ...
(Date:3/29/2017)... 29, 2017  The Pharmaceutical Care Management Association (PCMA) ... report on patient out-of-pocket spending: ... Services (CMS), the average amount spent out-of-pocket for drugs ... spending in 2016, down from 23% in 2006. ... not a coverage problem. Health plans don,t have unlimited ...
(Date:3/29/2017)... 29, 2017  Spiral Therapeutics, Inc. today announced ... Farma, S.L. for the worldwide exclusive rights to ... the field of otolaryngology for aggregate payments of ... The agreement provides Spiral with the option to ... product profile. Under the terms of the agreement, ...
Breaking Medicine Technology: